Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol

Area of Science:

• Oncology
• Nanomedicine
• Pharmacology

Background:

• Tocotrienol, a vitamin E derivative, exhibits potent in vitro anti-cancer properties.
• Current limitations in tocotrienol therapy include poor tumor-specific delivery after intravenous administration.
• Developing targeted delivery systems is crucial for enhancing tocotrienol's therapeutic potential.

Purpose of the Study:

• To evaluate a novel tumor-targeted vesicular formulation of tocotrienol.
• To assess the efficacy of this formulation in suppressing A431 epidermoid carcinoma and B16-F10 melanoma growth.
• To determine the in vitro and in vivo anti-cancer activity and toxicity profile of the targeted nanomedicine.

Main Methods:

• Formulation of transferrin-bearing multilamellar vesicles encapsulating tocotrienol (α-T3).
• In vitro assessment of therapeutic efficacy on A431 cell lines.
• In vivo studies involving intravenous administration in tumor-bearing mouse models (A431 and B16-F10).
• Evaluation of tumor suppression rates, mouse survival, and visible toxicity.

Main Results:

• Transferrin-bearing vesicles significantly enhanced in vitro therapeutic efficacy by at least 52-fold compared to free tocotrienol.
• Intravenous administration of the targeted formulation led to tumor suppression in 30% of A431 and 60% of B16-F10 tumors.
• Significant enhancement in mouse survival (>13 days) was observed compared to controls receiving free drug solution.
• No visible toxicity was noted with the targeted nanomedicine.

Conclusions:

• Novel transferrin-bearing vesicular formulation of tocotrienol demonstrates significantly improved therapeutic efficacy.
• This tumor-targeted nanomedicine shows promise for enhanced cancer treatment response.
• The developed tocotrienol-based nanomedicine offers a potential strategy to overcome delivery limitations and improve anti-cancer outcomes.